WHO expert panel recommends Oxford University-Serum Institute's anti-malaria vaccine
malaria vaccine jointly developed by the University of Oxford and the Serum Institute of India (SII), leveraging Novavax's adjuvant, has now been recommended for use by the World Health Organization's (WHO) Strategic Advisory Group of Experts (SAGE) and the Malaria Policy Advisory Group (MPAG), paving the way for a global roll-out soon.
The R21/Matrix-M™ malaria vaccine is an easily deployable vaccine that can be manufactured at mass scale and modest cost, enabling as many as hundreds of millions of doses to be supplied to countries which are suffering a significant malaria burden.
Enhance Your Healthcare Expertise with High-Impact Courses
Offering CollegeCourseWebsiteIndian School of BusinessISB Healthcare ManagementVisitIIM KozhikodeIIMK Healthcare Management & Analytics ProgrammeVisitSII has already established production capacity for 100 million doses per annum, which will be doubled over the next two years.
The WHO's recommendation today is required for UNICEF to procure and GAVI to purchase the vaccine, paving the way for vaccination of children in populations most at risk.
R21/Matrix-M malaria vaccine marks the culmination of 30 years of malaria vaccine research at the University of Oxford's Jenner Institute
Half a million people die from malaria every year across the world.
«For far too long, malaria has threatened the lives of billions of people across the globe, disproportionately affecting the most vulnerable amongst us,» said Adar Poonawalla, chief executive officer of SII.
«This is why the WHO recommendation and approval of the R21/Matrix-M vaccine marks a huge milestone on our journey to combat this life-threatening disease, showing what exactly can be achieved when the public and private sector,
